Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Statement By Medicare Rights Center President Joseph Baker On Recent Progress Toward Passage Of Health Reform Legislation
Yesterday"s Senate HELP Committee"s vote for a health reform bill and the beginning today of the committee markup process in the House of Representatives mark significant steps forward on the path to comprehensive health reform.
generic viagra online
CPhA Applauds Efforts To Help Seniors Afford Prescription Medications
Congressional leaders and leading pharmaceutical companies have come up with a plan to reduce medication costs for millions of senior citizens enrolled in the Medicare Part D Prescription Drug program. In combination with other discount programs and rebates, the savings to the U.S. government could represent $80 billion. The Pharmaceutical Research and Manufacturers of America (PhRMA) is leading the charge to specifically close the coverage gap for patients whose medications costs fall into the "doughnut hole."
News of the day
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties Of TAK-652 For The Treatment Of HIV
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.
Medical Devices

HHS To Propose Removal Of HIV From List Preventing Foreigners U.S. Entry

HHS this week will issue proposed regulations to remove HIV from the list of "communicable diseases of public health significance," effectively lifting the ban on HIV-positive foreign residents from entering the country, Newsday reports (Reddy, 6/29). Last year, then-President George W. Bush signed into law a provision to remove HIV from the HHS list, the Washington Post"s blog, "44," reports. The proposed rule has to be published in the Federal Register, and then undergo a 45-day comment period before becoming finalized (Hsu, 6/29). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009